After 72 weeks, patients on the highest dose (36 mg) achieved an average weight reduction of 12.4% (about 27 lbs) compared to 0.9% on placebo
The 503A pathway for individual patient prescriptions by state-licensed pharmacies remains intact
In SURMOUNT-4, adults who had lost an average of 20.9% on Mounjaro then switched to placebo regained 14% of their starting weight over the following year, retaining only about a third of the weight loss theyd initially achieved
These may include: A gradual increase gives researchers and clinicians time to monitor tolerability and safety before moving to a higher dose
A: According to ro.co and standard medical practice, yes, switching medications is possible if: Experiencing intolerable side effects despite management strategies Inadequate weight loss response after appropriate trial period Other medical reasons make alternative more appropriate Considerations When Switching : Insurance coverage may differ between medications (new prior authorization required) Must restart dose escalation schedule with new medication Some side effects common across all GLP-1s (switching may not resolve all issues) Switching incurs additional costs and time delay Provider discretion required Discuss thoroughly with provider before deciding to switch
3 Long-term low-dose or cycling strategy: Some patients remain on a lower maintenance dose long term
